Pomalidomide

(Pomalyst®)

Pomalyst®

Latest News

loading GIF

Drug updated on 4/24/2024

Dosage FormCapsule (oral; 1 mg, 2 mg, 3 mg, 4 mg)
Drug ClassAntineoplastics
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • In combination with dexamethasone, indicated for the treatment of adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
  • Indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Pomalidomide (Pomalyst) combined with dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies and have shown disease progression. It is also used for treating AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy or in patients who are HIV-negative.
  • Information was derived from seven systematic reviews/meta-analyses, comparing pomalidomide to other treatments based on safety and effectiveness, specifically in the context of relapsed/refractory multiple myeloma.
  • Compared to doublet regimens, pomalidomide as part of triplet regimens showed higher overall response rates. However, when matched against other novel treatments like daratumumab and isatuximab-based therapies using network meta-analysis, these options showed better overall response rates than those including Pomalyst.
  • An indirect comparison suggested that pomalidomide combined with dexamethasone is effective; however, ixazomib had a significant impact on progression-free survival among several treatments, indicating variable effectiveness depending upon the therapeutic combinations.
  • Adverse events associated with pomalidomide varied widely; however, hematologic adverse events such as neutropenia and anemia were particularly noteworthy across studies, suggesting a need for vigilance regarding hematological safety during its use.
  • Subgroup analysis revealed that the efficacy of pomalidomide seemed pronounced in subpopulations previously treated with lenalidomide, hinting at its role in overcoming lenalidomide resistance.

Product Monograph / Prescribing Information

Document TitleYearSource
Pomalyst (pomalidomide) Prescribing Information.2021Celgene Corporation Summit, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Clinical practice guideline: multiple myeloma.2022Myeloma Australia
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. 2020Journal of the National Comprehensive Cancer Network
Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline.2019Journal of Clinical Oncology
AIDS-Related Kaposi Sarcoma, Version 2.2019. 2019Journal of the National Comprehensive Cancer Network
Clinical practice guideline: multiple myeloma. 2019Myeloma Australia